Company intelligence / Profile preview

Immune Targeting Systems

London, United Kingdomventureradar.com ↗

Ownership: Private
Development stage: Phase 1

Overview

The company demonstrated successful T-cell responses in multiple clinical studies before being acquired by Vaxin in 2015. A Phase I/II clinical study for hepatitis B therapeutic vaccine was expected to begin in the first half of 2015.

Therapeutic areas: Infectious Diseases
Modalities: Synthetic vaccinesT-cell vaccines
Industry: Biotech

Drug pipeline

3 assets

Flunisyn

Phase 1

Indications: Influenza A

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Immune Targeting Systems.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Immune Targeting Systems.

Explore the full profile